Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026

Tvardi Therapeutics, Inc.

2025-Q3 EPS reported -$2.50

Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.
Phase 2 REVERT Liver Cancer (TTI-101) topline data expected H1 2026; interim showed activity.
TTI-109 healthy volunteer study started; results also H1 2026.
REVERT IPF trial preliminary data in October did not meet goals; further analysis underway.
R&D expenses $3.6M, down from $4.8M; G&A $2.3M, up from $0.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.